LEXINGTON, Mass., May 2, 2019 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology
company devoted to developing and commercializing next-generation
medicines to improve the lives of patients with immune-mediated
diseases, today announced that the Company will host a conference
call on Thursday, May 9, 2019, at
8:00 a.m. EDT to discuss financial
results and provide a corporate update for the quarter ended
March 31, 2019. The dial-in
numbers are 1-877-266-8979 for domestic callers and 1-412-317-5231
for international callers. A live webcast of the conference
call will also be available on the investor relations page of the
Aldeyra Therapeutics corporate website
at www.aldeyra.com.
After the live webcast, the event will remain archived on the
Aldeyra Therapeutics website for one year.
About Aldeyra Therapeutics
Aldeyra Therapeutics
is a biotechnology company devoted to developing and
commercializing next-generation medicines to improve the lives of
patients with immune-mediated diseases. Aldeyra's lead product
candidate, reproxalap, is a first-in-class treatment in late-stage
development for dry eye disease, allergic conjunctivitis,
noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The
company is also developing other product candidates for
proliferative vitreoretinopathy and other retinal diseases,
post-transplant lymphoproliferative disease, autoimmune disease,
metabolic disease, and cancer. None of Aldeyra's product candidates
have been approved for sale in the U.S. or elsewhere.
Corporate Contact:
David
McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com
Investor Contact:
Chris
Brinzey
Westwicke, an ICR Company
Tel: 339-970-2843
Chris.brinzey@westwicke.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-report-first-quarter-2019-financial-results-and-host-conference-call-on-thursday-may-9-2019-300842305.html
SOURCE Aldeyra Therapeutics, Inc.